U.S. Food and Drug Administration approved the first liquid biopsy companion diagnostic for sarcoma biopsy market
The
growing prevalence of osteosarcoma is expanding the size of the global sarcoma
biopsy market. Osteosarcoma is the most common type of cancer affecting bones.
According to the American Cancer Society, IN January 2020, around 800 to 900
new cases of osteosarcoma are diagnosed in the U.S. each year, with around 50%
occurs in children and teenagers. Also, the advent of an advanced diagnostic
test for diagnosing cancer is again expected to foster the growth of the
sarcoma biopsy market. Needle biopsy and surgical biopsy are the
fastest-growing segments in the sarcoma biopsy market.
North
America is expected to hold a dominant position in the global sarcoma
biopsy market due to increasing healthcare expenditure in the U.S. For
instance, according to the Committee for a Responsible Federal Budget, in 2017,
the U.S. spent around the US $ 3.5 trillion, or 18% of the total GDP, on health
expenditures, which is more than twice the average among developed countries.
In January 2020, the U.S. Food and
Drug Administration approved Tazverik (tazemetostat) for the treatment of
adults and pediatric patients aged 16 years and older with metastatic or
locally advanced epithelioid sarcoma
In August 2020, U.S. Food and Drug
Administration approved the first liquid biopsy companion diagnostic that also
uses next-generation sequencing (NGS) technology to identify patients with
specific types of mutations of the epidermal growth factor receptor (EGFR) gene
in a deadly form of metastatic non-small cell lung cancer (NSCLC)
In April 2021, Genetron Holdings
Limited a precision oncology platform company in China that specializes in
molecular profiling tests, early cancer screening products, and companion
diagnostics development, announced the release of 22 research results at the
American Association for Cancer Research Annual Meeting 2021 (AACR 2021)
Sarcoma
can be one of the most fatal forms of cancer, and as such, there is an
increased interest in Sarcoma Biopsies amongst both the public and healthcare
professionals. It is therefore of great importance that Sarcoma Biopsies is
obtained from an experienced and reliable source. With this in mind, it would
be safe to say that the medical sarcoma biopsy industry would see phenomenal
growth in terms of both patients and revenue. Sarcoma Biopsies is highly
flexible in terms of the patients it can accommodate and their respective
requirements. Not only can a patient choose to undergo a sarcoma biopsy either
alone or in conjunction with another form of surgical procedure, but they can
also choose to undergo a full-body surgical procedure as well as receive a
non-surgical procedure
Comments
Post a Comment